Literature DB >> 29205349

Perioperative cytokine levels portend early death after pancreatectomy for ductal adenocarcinoma.

Heather L Lewis1, Jeff M Chakedis1, Erin Talbert2, Ericka Haverick1, Priyani Rajasekera1, Philip Hart3, Mark Bloomston4, Mary Dillhoff1, Timothy M Pawlik1, Denis Guttridge2, Carl R Schmidt1.   

Abstract

BACKGROUND: Soluble signaling molecules may play an important role in malignant pathogenesis. We hypothesize that perioperative cytokine levels are associated with outcomes in patients with pancreatic adenocarcinoma (PDAC) undergoing surgical resection.
METHODS: One hundered and eighteen patients with benign or malignant pancreatic disease were enrolled in a prospective study through a protocol for banking biologic samples. Peripheral blood was drawn at time of operation, and a multiplex cytokine assay was performed. Statistical analysis was via χ2 and Kaplan Meier methods.
RESULTS: Of 118 patients enrolled, 85 (72%) had a diagnosis of PDAC, and 60 (70%) ultimately underwent partial pancreatectomy. Cytokine levels were not associated with postoperative complications in this initial cohort. A plasma level of monocyte chemoattractant protein-1 (MCP-1) pg/mL ≤118 was associated with better overall survival (OS) (median survival 21 months vs 12.8 months, P = 0.023), as was non-detectable interleukin-8 (IL-8) (19 months) versus detectable IL-8 (12.8 months, P = 0.05). Patients with both MCP-1 >118 pg/mL and detectable IL-8 had a median survival of 10.6 months (P = 0.028).
CONCLUSIONS: MCP-1 and IL-8 cytokine levels are associated with decreased survival following pancreatectomy for PDAC, and may be useful biomarkers. Measurement of these cytokine levels at different time points in future investigations will be important to validate these findings.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  IL-8; MCP-1; cytokines; pancreatectomy; pancreatic adenocarcinoma

Mesh:

Substances:

Year:  2017        PMID: 29205349     DOI: 10.1002/jso.24940

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

Review 1.  Is the C-C Motif Ligand 2-C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?

Authors:  Hiroaki Iwamoto; Kouji Izumi; Atsushi Mizokami
Journal:  Int J Mol Sci       Date:  2020-12-07       Impact factor: 5.923

Review 2.  Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments.

Authors:  Juha J Hulmi; Tuuli A Nissinen; Fabio Penna; Andrea Bonetto
Journal:  Cells       Date:  2021-02-28       Impact factor: 6.600

3.  Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

Authors:  Tuuli A Nissinen; Jaakko Hentilä; Fabio Penna; Anita Lampinen; Juulia H Lautaoja; Vasco Fachada; Tanja Holopainen; Olli Ritvos; Riikka Kivelä; Juha J Hulmi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-05-02       Impact factor: 12.910

4.  Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.

Authors:  Sara Chiappalupi; Guglielmo Sorci; Aleksandra Vukasinovic; Laura Salvadori; Roberta Sagheddu; Dario Coletti; Giorgia Renga; Luigina Romani; Rosario Donato; Francesca Riuzzi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-03-11       Impact factor: 12.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.